Finch Therapeutics Group (NASDAQ:FNCH) Stock Price Up 0.8% – What’s Next?

Finch Therapeutics Group, Inc. (NASDAQ:FNCH)’s stock price rose 0.8% on Tuesday . The stock traded as high as $12.13 and last traded at $12.05. Approximately 5,118 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 28,449 shares. The stock had previously closed at $11.95.

Finch Therapeutics Group Stock Down 4.2 %

The business’s fifty day moving average is $11.91 and its 200-day moving average is $6.20. The company has a market cap of $18.47 million, a PE ratio of -1.36 and a beta of 1.34.

Finch Therapeutics Group (NASDAQ:FNCH) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($3.01) EPS for the quarter.

Institutional Trading of Finch Therapeutics Group

An institutional investor recently bought a new position in Finch Therapeutics Group stock. Lake Street Advisors Group LLC bought a new position in Finch Therapeutics Group, Inc. (NASDAQ:FNCH) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 21,206 shares of the company’s stock, valued at approximately $56,000. Lake Street Advisors Group LLC owned approximately 1.32% of Finch Therapeutics Group as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 21.77% of the company’s stock.

Finch Therapeutics Group Company Profile

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.